Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
EBS Quote, Financials, Valuation and Earnings
Last price:
$10.94
Seasonality move
:
3.26%
Day range:
$10.71 - $11.23
52-week range:
$4.02 - $14.06
Dividend yield:
0%
P/E ratio:
8.45x
P/S ratio:
0.77x
P/B ratio:
0.99x
Volume:
567.6K
Avg. volume:
789.5K
1-year change:
39.41%
Market cap:
$574M
Revenue:
$1B
EPS (TTM):
$1.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$217.5M | $0.11 | 23.76% | -94.67% | $13.50 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.3% | 75.74% | $104.75 |
|
IRON
Disc Medicine, Inc.
|
-- | -$1.70 | -- | -69.44% | $103.42 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $6.91 | 36.93% | 135.67% | $1,211.21 |
|
MTVA
MetaVia, Inc.
|
-- | -$0.65 | -- | -69.19% | $91.00 |
|
PEN
Penumbra, Inc.
|
$367.2M | $1.11 | 14.25% | 8.28% | $348.53 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$10.93 | $13.50 | $574M | 8.45x | $0.00 | 0% | 0.77x |
|
BSX
Boston Scientific Corp.
|
$74.58 | $104.75 | $110.6B | 38.46x | $0.00 | 0% | 5.55x |
|
IRON
Disc Medicine, Inc.
|
$61.36 | $103.42 | $2.3B | -- | $0.00 | 0% | -- |
|
LLY
Eli Lilly & Co.
|
$1,009.52 | $1,211.21 | $952.3B | 44.69x | $1.73 | 0.62% | 14.11x |
|
MTVA
MetaVia, Inc.
|
$1.55 | $91.00 | $39.4M | -- | $0.00 | 0% | -- |
|
PEN
Penumbra, Inc.
|
$339.36 | $348.53 | $13.3B | 81.10x | $0.00 | 0% | 9.97x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
53.53% | 4.437 | 144.36% | 2.93x |
|
BSX
Boston Scientific Corp.
|
33.07% | 0.200 | 8.46% | 0.94x |
|
IRON
Disc Medicine, Inc.
|
5.13% | 1.663 | 1.34% | 23.03x |
|
LLY
Eli Lilly & Co.
|
62.31% | -0.536 | 4.56% | 0.71x |
|
MTVA
MetaVia, Inc.
|
1.23% | 1.551 | 0.03% | 1.69x |
|
PEN
Penumbra, Inc.
|
13.77% | -1.022 | 2.19% | 3.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$129.1M | $76.8M | 6.29% | 14.25% | 33.23% | -$5.7M |
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
IRON
Disc Medicine, Inc.
|
-$87K | -$67.7M | -31.4% | -32.82% | -- | -$47.8M |
|
LLY
Eli Lilly & Co.
|
$15.9B | $9B | 34.71% | 104.39% | 46.58% | $254.2M |
|
MTVA
MetaVia, Inc.
|
-$5K | -$3.5M | -193.95% | -196.71% | -- | -$3M |
|
PEN
Penumbra, Inc.
|
$238M | $48.8M | 11.35% | 13.4% | 13.77% | $42M |
Emergent BioSolutions, Inc. vs. Competitors
-
Which has Higher Returns EBS or BSX?
Boston Scientific Corp. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of 12.68%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Boston Scientific Corp.'s return on equity of 12.55%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B BSXBoston Scientific Corp.68.5% $0.45 $36.4B -
What do Analysts Say About EBS or BSX?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 23.51%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 40.45%. Given that Boston Scientific Corp. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Boston Scientific Corp. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 BSXBoston Scientific Corp.25 0 0 -
Is EBS or BSX More Risky?
Emergent BioSolutions, Inc. has a beta of 2.346, which suggesting that the stock is 134.572% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.
-
Which is a Better Dividend Stock EBS or BSX?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or BSX?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Emergent BioSolutions, Inc.'s net income of $51.2M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.45x while Boston Scientific Corp.'s PE ratio is 38.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.77x versus 5.55x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.77x 8.45x $231.1M $51.2M BSXBoston Scientific Corp.5.55x 38.46x $5.3B $670M
-
Which has Higher Returns EBS or IRON?
Disc Medicine, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of --. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Disc Medicine, Inc.'s return on equity of -32.82%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B IRONDisc Medicine, Inc.-- -$1.77 $604.4M -
What do Analysts Say About EBS or IRON?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 23.51%. On the other hand Disc Medicine, Inc. has an analysts' consensus of $103.42 which suggests that it could grow by 68.54%. Given that Disc Medicine, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Disc Medicine, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 IRONDisc Medicine, Inc.12 0 0 -
Is EBS or IRON More Risky?
Emergent BioSolutions, Inc. has a beta of 2.346, which suggesting that the stock is 134.572% more volatile than S&P 500. In comparison Disc Medicine, Inc. has a beta of 0.885, suggesting its less volatile than the S&P 500 by 11.549%.
-
Which is a Better Dividend Stock EBS or IRON?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Disc Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Disc Medicine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or IRON?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than Disc Medicine, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Disc Medicine, Inc.'s net income of -$62.3M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.45x while Disc Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.77x versus -- for Disc Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.77x 8.45x $231.1M $51.2M IRONDisc Medicine, Inc.-- -- -- -$62.3M
-
Which has Higher Returns EBS or LLY?
Eli Lilly & Co. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of 34.4%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Eli Lilly & Co.'s return on equity of 104.39%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B LLYEli Lilly & Co.82.52% $7.02 $70.4B -
What do Analysts Say About EBS or LLY?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 23.51%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Emergent BioSolutions, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Emergent BioSolutions, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 LLYEli Lilly & Co.18 6 0 -
Is EBS or LLY More Risky?
Emergent BioSolutions, Inc. has a beta of 2.346, which suggesting that the stock is 134.572% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.
-
Which is a Better Dividend Stock EBS or LLY?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios EBS or LLY?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Emergent BioSolutions, Inc.'s net income of $51.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.45x while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.77x versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.77x 8.45x $231.1M $51.2M LLYEli Lilly & Co.14.11x 44.69x $19.3B $6.6B
-
Which has Higher Returns EBS or MTVA?
MetaVia, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of --. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat MetaVia, Inc.'s return on equity of -196.71%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B MTVAMetaVia, Inc.-- -$1.52 $6.4M -
What do Analysts Say About EBS or MTVA?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 23.51%. On the other hand MetaVia, Inc. has an analysts' consensus of $91.00 which suggests that it could grow by 5770.97%. Given that MetaVia, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe MetaVia, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 MTVAMetaVia, Inc.2 0 0 -
Is EBS or MTVA More Risky?
Emergent BioSolutions, Inc. has a beta of 2.346, which suggesting that the stock is 134.572% more volatile than S&P 500. In comparison MetaVia, Inc. has a beta of 0.271, suggesting its less volatile than the S&P 500 by 72.937%.
-
Which is a Better Dividend Stock EBS or MTVA?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaVia, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. MetaVia, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or MTVA?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than MetaVia, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than MetaVia, Inc.'s net income of -$3.4M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.45x while MetaVia, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.77x versus -- for MetaVia, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.77x 8.45x $231.1M $51.2M MTVAMetaVia, Inc.-- -- -- -$3.4M
-
Which has Higher Returns EBS or PEN?
Penumbra, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of 12.93%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Penumbra, Inc.'s return on equity of 13.4%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B PENPenumbra, Inc.67.1% $1.17 $1.6B -
What do Analysts Say About EBS or PEN?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 23.51%. On the other hand Penumbra, Inc. has an analysts' consensus of $348.53 which suggests that it could grow by 2.7%. Given that Emergent BioSolutions, Inc. has higher upside potential than Penumbra, Inc., analysts believe Emergent BioSolutions, Inc. is more attractive than Penumbra, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 PENPenumbra, Inc.2 13 1 -
Is EBS or PEN More Risky?
Emergent BioSolutions, Inc. has a beta of 2.346, which suggesting that the stock is 134.572% more volatile than S&P 500. In comparison Penumbra, Inc. has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.405%.
-
Which is a Better Dividend Stock EBS or PEN?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Penumbra, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Penumbra, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or PEN?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are smaller than Penumbra, Inc. quarterly revenues of $354.7M. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Penumbra, Inc.'s net income of $45.9M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.45x while Penumbra, Inc.'s PE ratio is 81.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.77x versus 9.97x for Penumbra, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.77x 8.45x $231.1M $51.2M PENPenumbra, Inc.9.97x 81.10x $354.7M $45.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 23
RingCentral, Inc. [RNG] is down 6.68% over the past day.
Sell
9
FROG alert for Feb 23
JFrog Ltd. [FROG] is down 4.85% over the past day.
Buy
72
SNSE alert for Feb 23
Sensei Biotherapeutics, Inc. [SNSE] is down 6.15% over the past day.
